|
|
 | | | |
- close
- close
- close
- close
| |||||||||
These excerpts taken from the SPPI 10-K filed Mar 31, 2009. Principles
of Consolidation and Basis of Presentation
The consolidated financial statements include the accounts of
the Company, our wholly-owned subsidiaries, and joint ventures
the Company controls, or of which it is the primary beneficiary.
We evaluate the need to consolidate joint ventures based on
standards set forth in Financial Accounting Standards Board
(“FASB”) Financial Interpretation (“FIN”)
No. 46R, Consolidation of Variable Interest Entities
(“FIN 46R”). Investments by outside parties
in our consolidated entities are recorded as Minority Interest
in Consolidated entities in our accounts, and stated net after
allocation of income and losses in the entity.
As of December 31, 2008, we had two consolidated
subsidiaries: OncoRx Pharma Private Limited
(“OncoRx”), 100% owned, organized in Mumbai, India in
2008 and Spectrum Pharmaceuticals GmbH, wholly-owned inactive
subsidiary, incorporated in Switzerland in April 1997; and two
consolidated joint ventures: RIT Oncology, LLC
(“RIT”), organized in Delaware in October 2008; and
Spectrum Pharma Canada, organized in Quebec, Canada in January
2008. During 2008, we dissolved NeoJB LLC (“NeoJB”),
which was 80% owned by us and organized in Delaware in April
2002.
We have eliminated all significant intercompany accounts and
transactions.
Principles of Consolidation and Basis of Presentation The consolidated financial statements include the accounts of the Company, our wholly-owned subsidiaries, and joint ventures the Company controls, or of which it is the primary beneficiary. We evaluate the need to consolidate joint ventures based on standards set forth in Financial Accounting Standards Board (“FASB”) Financial Interpretation (“FIN”) No. 46R, Consolidation of Variable Interest Entities (“FIN 46R”). Investments by outside parties in our consolidated entities are recorded as Minority Interest in Consolidated entities in our accounts, and stated net after allocation of income and losses in the entity. As of December 31, 2008, we had two consolidated subsidiaries: OncoRx Pharma Private Limited (“OncoRx”), 100% owned, organized in Mumbai, India in 2008 and Spectrum Pharmaceuticals GmbH, wholly-owned inactive subsidiary, incorporated in Switzerland in April 1997; and two consolidated joint ventures: RIT Oncology, LLC (“RIT”), organized in Delaware in October 2008; and Spectrum Pharma Canada, organized in Quebec, Canada in January 2008. During 2008, we dissolved NeoJB LLC (“NeoJB”), which was 80% owned by us and organized in Delaware in April 2002. We have eliminated all significant intercompany accounts and transactions. These excerpts taken from the SPPI 10-K filed Mar 14, 2008. Principles
of Consolidation and Basis of Presentation
The consolidated financial statements include the accounts of
the Company and of our wholly-owned and majority-owned
subsidiaries. As of December 31, 2007, we had two
subsidiaries: NeoJB LLC (NeoJB), 80% owned, organized in
Delaware in April 2002 and Spectrum Pharmaceuticals GmbH,
wholly-owned inactive subsidiary, incorporated in Switzerland in
April 1997. During 2006, NeoGene Technologies, Inc., an inactive
subsidiary, was dissolved. We have eliminated all significant
intercompany accounts and transactions.
Investments by outside parties in our majority-owned
consolidated subsidiary are recorded as Minority Interest in
Consolidated Subsidiary in our accounts, and stated net after
allocation of income and losses in the subsidiary.
Principles of Consolidation and Basis of Presentation The consolidated financial statements include the accounts of the Company and of our wholly-owned and majority-owned subsidiaries. As of December 31, 2007, we had two subsidiaries: NeoJB LLC (NeoJB), 80% owned, organized in Delaware in April 2002 and Spectrum Pharmaceuticals GmbH, wholly-owned inactive subsidiary, incorporated in Switzerland in April 1997. During 2006, NeoGene Technologies, Inc., an inactive subsidiary, was dissolved. We have eliminated all significant intercompany accounts and transactions. Investments by outside parties in our majority-owned consolidated subsidiary are recorded as Minority Interest in Consolidated Subsidiary in our accounts, and stated net after allocation of income and losses in the subsidiary. This excerpt taken from the SPPI 10-K filed Mar 14, 2007. Principles of Consolidation and Basis of Presentation The consolidated financial statements include the accounts of the Company and of our wholly-owned and majority-owned subsidiaries. As of December 31, 2006, we had two subsidiaries: NeoJB LLC (NeoJB), 80% owned, organized in Delaware in April 2002 and Spectrum Pharmaceuticals GmbH, wholly-owned inactive subsidiary, incorporated in Switzerland in April 1997. During 2006, NeoGene Technologies, Inc., an inactive subsidiary, was dissolved. We have eliminated all significant intercompany accounts and transactions. Investments by outside parties in our majority-owned consolidated subsidiary are recorded as Minority Interest in Consolidated Subsidiary in our accounts, and stated net after allocation of income and losses in the subsidiary. | EXCERPTS ON THIS PAGE:
|
| |||||||
